Study Details

Back to Search Results

A Study to Evaluate the Pharmacokinetics, Pharmacodynamics and Safety of ASP8232 in subjects with renal impairment and in Type 2 Diabetes Mellitus Subjects with Chronic Kidney Disease

This trial is complete
The study has ended normally, and participants are no longer being examined or treated (that is, the last participant's last visit has occurred).

Clinicaltrials.gov ID

The unique identification code given to each clinical study upon registration at ClinicalTrials.gov.
NCT02218099

Astellas Study ID

The unique identification code given by the study sponsor.

8232-CL-0002

EudraCT ID

The unique identification code given to each clinical study upon registration at EudraCT (European Union Drug Regulating Authorities Clinical Trials Database).

2013-000680-89

Follow Trial

Condition

Healthy Volunteer, Other, Kidney Disease, Adult Onset Diabetes

Phase

These clinical trials are usually the first time an experimental treatment is studied in a small group of people.

Phase 1

Age

35 years - 80 years

Sex

Female & Male

Product

N/A

Type

A type of clinical study in which participants are assigned to groups that receive one or more intervention/treatment (or no intervention) so that researchers can evaluate the effects of the interventions on biomedical or health-related outcomes.

Interventional

Trial Dates

Sep 2013 - Sep 2014

Masking

Triple (Participant, Care Provider, Investigator)

Enrollment number

55

A Phase 1 Study to Evaluate the Effect of Renal Impairment on the Pharmacokinetics, Pharmacodynamics and Safety of ASP8232 (Part 1) and a Multiple Dose, Placebo-controlled Exploratory Safety, Pharmacokinetic and Pharmacodynamic Study in Type 2 Diabetes Mellitus Subjects with Chronic Kidney Disease (Part 2)

Study summary

Study documents

Study Documents, including study results, are available after a study is completed or terminated, according to Astellas Transparency policy.

Get More Information

Would you like more information about clinical trial sites that are recruiting participants for A Study to Evaluate the Pharmacokinetics, Pharmacodynamics and Safety of ASP8232 in subjects with renal impairment and in Type 2 Diabetes Mellitus Subjects with Chronic Kidney Disease? Contact us by filling our your information to the right and we’ll respond to you.

By clicking ["Continue/Submit"], you agree that Astellas may contact you by email with information to help you connect with clinical trial sites. While we can connect you to clinical trial sites, we cannot answer questions about any investigational therapy through email. Your consent to receiving emails is not a requirement to participate in a clinical trial or study. For more information, including how to unsubscribe at any time, see our Privacy Notice & Cookies Policy.

Locations

Site: 37301

Chisinau, Republic of Moldova

Site: 35901

Sofia, Bulgaria, 1612

Site: 40001

Bucharest, Romania, 10731

The purpose of this website is to offer education and information to patients and their families and friends, the public, and healthcare professionals about the clinical trial process. In addition, the website will provide specific information about Astellas clinical trials. Please read the complete Astellas Transparency Policy to learn about the clinical trial information available on this website

© ASTELLAS PHARMA GLOBAL DEVELOPMENT, INC.

POWERED BY:

Pharma Intelligence logo